Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jDAPA-PD: Dapagliflozin for Peritoneal Dialysis Patients with Chronic Heart Failure
jRCT1031230624Recruiting
- Sponsor
- Niigata University Medical and Dental Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in chronic heart failure (CHF), chronic kidney disease (CKD) and end-stage kidney disease (ESKD) comparing Dapagliflozin plus standard of care with Standard of care alone (2 arms). Primary endpoint: Change in extracellular water from baseline to week 24. Started Jun 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic heart failure (CHF)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT1031230624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230624.